|
|
Article: Indevus Licenses Antifungal Compound, Plans Clinical Trials.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Indevus Pharmaceuticals Inc. expanded its pipeline after acquiring worldwide rights to an antifungal compound from Aventis SA.
The Lexington, Mass.-based firm licensed exclusive worldwide rights to aminocandin, a member of a new class of antifungal compounds being developed to treat a spectrum of systemic and invasive infections.
"Our business model is one of identifying and licensing in promising clinical or late preclinical candidates for development across a variety of indications," William Boni, vice president of corporate communications at Indevus, told BioWorld Today. "This compound met the bill. It had a very interesting ...